Peripheral polyneuropathy during treatment with alpha-2 interferon.
Cudillo
L
L
Cantonetti
M
M
Venditti
A
A
Lentini
R
R
Rossini
P M
PM
Caramia
M
M
Masi
M
M
Papa
G
G
D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D007370:Interferon Type I / Q000009:adverse effects* / Q000627:therapeutic use; D007866:Leg; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009046:Motor Neurons / Q000187:drug effects; D009133:Muscular Atrophy / Q000139:chemically induced; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D011994:Recombinant Proteins
D007155:Immunologic Factors; D007370:Interferon Type I; D011994:Recombinant Proteins